Skip to content
value.today

Clovis Oncology, Inc.

Total raised
$146 M
1 round on record
Latest round
$146 M
May 2009
First round on record
May 2009
Today
Private
See the company page

Clovis Oncology, Inc. is listed today as Clovis Oncology: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Clovis Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2013$192 MIssued in a merger or acquisition$50 to $250 million

Clovis Oncology, Inc.: Private sale, Nov 2013

Investors in this round

9 investors had bought by the notice of Nov 27, 2013: 8 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Clovis Oncology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$192 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew R. Allen · Executive Officer · Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer
  • Erle T. Mast · Executive Officer · Executive Vice President and Chief Financial Officer
  • Gillian C. Ivers-Read · Executive Officer · Executive Vice President of Technical Operations and Chief Regulatory Officer
  • Patrick J. Mahaffy · Executive Officer, Director · President, Chief Executive Officer and Director
  • Steven L. Hoerter · Executive Officer · Senior Vice President, Commercial
  • Brian G. Atwood · Director
  • Edward J. McKinley · Director
  • Ginger L. Graham · Director
  • James C. Blair · Director
  • Keith L. Flaherty · Director
  • M. James Barret · Director
  • Paul C. Klingenstein · Director
  • Thorlef J. Spickschen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Erle T. Mast, See Clarification Box in Item #3 above. Source: SEC Form D, newest notice filed Nov 27, 2013. Read the notice at the SEC.

equitySEC
May 2009$146 MNo. 1$50 to $250 million

Clovis Oncology, Inc.: Raise no. 1, May 2009

Investors in this round

19 investors had bought by the notice of May 18, 2011: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Clovis Oncology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$146 M of $146 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew R. Allen · Executive Officer · Executive Vice President, Chief Medical Officer
  • Erle T. Mast · Executive Officer · Executive Vice President, Chief Financial Officer and Secretary
  • Gillian C. Ivers-Read · Executive Officer · Executive Vice President, Regulatory Affairs and Technical Operations
  • Patrick J. Mahaffy · Executive Officer · President and Chief Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Erle T. Mast, See Clarification Box in Item #3 above. Source: SEC Form D and 2 amendments, newest notice filed May 18, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Clovis Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2013).

    SEC Form D · Nov 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2013

That is all the official record says: Clovis Oncology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Clovis Oncology, Inc. are on record.

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Clovis Oncology, Inc.
InvestorKindAmountRoundRoleSource
Andrew R. AllenPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock (Form 3, 2011)SEC Form 3
Domain Parters VII L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
DP VII Associates LPFund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Edward J. McKinleyPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock, director (Form 3, 2011)SEC Form 3
Erle T. MastPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock (Form 3, 2011)SEC Form 3
Gillian C. IVers-ReadPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock (Form 3, 2011)SEC Form 3
NEA 13 GP, LtdCompanynot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
NEA Partners 13, Limited PartnershipFund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
New Enterprise Associates 13 LPFund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Patrick J. MahaffyPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock, director (Form 3, 2011)SEC Form 3
Thorlef SpickschenPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock, director (Form 3, 2011)SEC Form 3
Versant Side Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Versant Venture Capital IV, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Versant Ventures IV, LLCVenture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Clovis Oncology, Inc.
NameRoleNamed in
Andrew R. AllenExecutive Vice President of Clinical and Pre-Clinical Development and Chief Medical OfficerNov 2013
Erle T. MastExecutive Vice President and Chief Financial OfficerNov 2013
Gillian C. Ivers-ReadExecutive Vice President of Technical Operations and Chief Regulatory OfficerNov 2013
Patrick J. MahaffyPresident, Chief Executive Officer and DirectorNov 2013
Steven L. HoerterSenior Vice President, CommercialNov 2013
Brian G. AtwoodDirectorNov 2013
Edward J. McKinleyDirectorNov 2013
Ginger L. GrahamDirectorNov 2013
James C. BlairDirectorNov 2013
Keith L. FlahertyDirectorNov 2013
M. James BarretDirectorNov 2013
Patrick J. MahaffyPresident, Chief Executive Officer and DirectorNov 2013
Paul C. KlingensteinDirectorNov 2013
Thorlef J. SpickschenDirectorNov 2013

About

Small pharmaceutical company.